It is an uncontested fact that prescription drugs are big business; brand name pharmaceutical companies invest millions of dollars each year to develop new and innovative drugs. In order to protect their new and innovative findings, pharmaceutical companies invest significant resources into registering their newly developed drugs as patents. In this regard, patent protection provides a period of market exclusivity to the owner of the patent and is an efficient tool to prevent third parties, including generic drug companies, from entering the market. However, once the patent protection period ends, the demand for brand name drugs drastically reduces as generic drug companies start manufacturing the same product at a significantly lower cost. As such, pharmaceutical companies may turn to other forms of IP protection in order to retain their market share after their patent and market exclusivity expires. 